Ysios Capital

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.

Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for HIV infection. Established in 2015 as a spin-off from the HIVACAT project, the company was founded by experts in the field, including Dr. Christian Brander and Bonaventura Clotet, who bring extensive experience in HIV research and biotech development. Aelix Therapeutics aims to leverage innovative immunogen designs to create vaccines that can elicit strong immune responses against HIV. By partnering with the HIVACAT consortium, the company has access to large cohorts of HIV-infected patients across multiple continents, enhancing its research capabilities and potential for impactful treatments. The company's work seeks to transform HIV treatment and pave the way for potential cures.

Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Anaconda Biomed, based in Barcelona, Spain, develops neuro-thrombectomy devices for acute ischemic stroke. Founded in 2015, the company designs and manufactures catheters and integrated thrombectomy systems, including the ANCD BRAIN, a third-generation stented aspiration thrombectomy system. Its offerings combine a delivery catheter, aspiration catheter, and a stent retriever to provide mechanical thrombectomy with thrombus extraction, aiming to remove clots and reduce stroke-related complications. The firm focuses on advancing minimally invasive solutions to treat AIS.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Anaconda Biomed, based in Barcelona, Spain, develops neuro-thrombectomy devices for acute ischemic stroke. Founded in 2015, the company designs and manufactures catheters and integrated thrombectomy systems, including the ANCD BRAIN, a third-generation stented aspiration thrombectomy system. Its offerings combine a delivery catheter, aspiration catheter, and a stent retriever to provide mechanical thrombectomy with thrombus extraction, aiming to remove clots and reduce stroke-related complications. The firm focuses on advancing minimally invasive solutions to treat AIS.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

Inbiomotion is a biotechnology company founded in 2010 by Dr. Roger Gomis, originating as a spin-off from IRB Barcelona and ICREA research institutions. The company specializes in developing and commercializing a biomarker that predicts metastasis in early-stage breast cancer patients. Its unique diagnostic assay leverages a highly selective single-gene biomarker, which has been shown to identify patients who may benefit from bisphosphonate adjuvant treatment, subsequently improving their overall survival and invasive disease-free survival rates. By utilizing this biomarker, Inbiomotion aims to evaluate the risk of metastases relapse from primary tumors, thereby facilitating a more personalized approach to treatment and advancing the clinical standard of care for breast cancer patients.

Aelix Therapeutics SL is a biotechnology company based in Barcelona, Spain, focused on developing therapeutic vaccines and immunotherapies for HIV infection. Established in 2015 as a spin-off from the HIVACAT project, the company was founded by experts in the field, including Dr. Christian Brander and Bonaventura Clotet, who bring extensive experience in HIV research and biotech development. Aelix Therapeutics aims to leverage innovative immunogen designs to create vaccines that can elicit strong immune responses against HIV. By partnering with the HIVACAT consortium, the company has access to large cohorts of HIV-infected patients across multiple continents, enhancing its research capabilities and potential for impactful treatments. The company's work seeks to transform HIV treatment and pave the way for potential cures.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Inbiomotion is a biotechnology company founded in 2010 by Dr. Roger Gomis, originating as a spin-off from IRB Barcelona and ICREA research institutions. The company specializes in developing and commercializing a biomarker that predicts metastasis in early-stage breast cancer patients. Its unique diagnostic assay leverages a highly selective single-gene biomarker, which has been shown to identify patients who may benefit from bisphosphonate adjuvant treatment, subsequently improving their overall survival and invasive disease-free survival rates. By utilizing this biomarker, Inbiomotion aims to evaluate the risk of metastases relapse from primary tumors, thereby facilitating a more personalized approach to treatment and advancing the clinical standard of care for breast cancer patients.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

SabirMedical S.L. is a biomedical research and development company based in Barcelona, Spain, founded in 2007. The company specializes in developing innovative technologies for diagnostics and patient care, particularly in the area of cardiovascular monitoring. Its offerings include non-invasive blood pressure monitoring systems that utilize pulse oximetry, designed for hospital, ambulatory, and home use. SabirMedical operates from the Bioincubator PCB-Santander space at Barcelona Science Park, emphasizing its commitment to advancing healthcare through technology.

Founded in 2004, Cellerix is a biotechnology company based in Tres Cantos, Spain. It specializes in the development of medicines using adult stem cells for treating gastroenterology, dermatology, and immune-based diseases.

Founded in 2004, Cellerix is a biotechnology company based in Tres Cantos, Spain. It specializes in the development of medicines using adult stem cells for treating gastroenterology, dermatology, and immune-based diseases.

Founded in 2004, Cellerix is a biotechnology company based in Tres Cantos, Spain. It specializes in the development of medicines using adult stem cells for treating gastroenterology, dermatology, and immune-based diseases.